Prophylactic and therapeutic vaccines for obesity.

Author: Ha Na NA ¹ ; Hun KIM ; Jae Hwan NAM
Author Information

1. Department of Infection and Obesity, Pennington Biomedical Research Center, Baton Rouge, LA, USA.
Publication Type:Review
Keywords: Adenovirus 36; Obesity; Vaccine
MeSH: Adenoviridae; Cause of Death; Chronic Disease; Ghrelin; Glucagon-Like Peptide 1; Obesity*; Peptide YY; Vaccines*
From:Clinical and Experimental Vaccine Research 2014;3(1):37-41
CountryRepublic of Korea
Language:English
Abstract: Chronic diseases such as obesity and diabetes are major causes of death and disability throughout the world. Many causes are known to trigger these chronic diseases, and infectious agents such as viruses are also pathological factors. In particular, it is considered that adenovirus 36 infections may be associated with obesity. If this is the case, a vaccine against adenovirus 36 may be a form of prophylaxis to combat obesity. Other types of therapeutic vaccines to combat obesity are also being developed. Recently, hormones such as glucagon-like peptide-1, ghrelin, and peptide YY have been studied as treatments to prevent obesity. This review describes the ongoing development of therapeutic vaccines to treat obesity, and the possibility of using inactivated adenovirus 36 as a vaccine and an anti-obesity agent.